Identification of a novel breast-cancer-anti-estrogen-resistance (BCAR2) locus by cell-fusion-mediated gene transfer in human breast-cancer cells

International Journal of Cancer

Volumn 72, Issue 4, 1997, Pages 700-705

  Dorssers, Lambert C J ^a   Veldscholte, Jos ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CELL FUSION; ESTROGEN THERAPY; GENE LOCUS; GENE TRANSFER; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL FUSION; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; GENE TRANSFER TECHNIQUES; HUMANS; HYBRID CELLS; ONCOGENES; TAMOXIFEN;

EID: 0030871325     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970807)72:4<700::AID-IJC24>3.0.CO;2-D     Document Type: Article

References (46)

1. BEATO, M., HERRLICH. P. and SCHUTZ, G., Steroid hormone receptors: many actors in search of a plot. Cell, 83, 851-857 (1995).
2. BERNS, E.M.J.J., FOEKENS, J.A., VAN STAVEREN, I.L., VAN PUTTEN, W.L.J., DE KONING. H.Y.W.C.M., PORTENGEN, H. und KLIJN, J.G.M., Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene. 159,11-18 (1995).
3. BOSHART, M., NITSCH, D. and SCHUETZ, G., Extinction of gene expression in somatic cell hybrids - a reflection of important regulatory mechanisms? Trends Genet., 9, 240-245 (1993).
4. CLARKE, R., DICKSON, R.B. and LIPPMAN, M.E., Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. Crit. Rev. Oncol. Hematol., 12, 1-23 (1992).
5. CLARKE, R., THOMPSON, E.W., LEONESSA, F., LIPPMAN, J., MCGARVEY, M., FRANDSEN, T.L. and BRÜNNER, N., Hormone resistance, invasiveness and metastatic potential in breast cancer. Breast Cancer Res. Treat., 24, 227-239 (1993).
6. Cox, D.R., BURMEISTER, M., PRICE, E.R., KIM, S. and MYERS, R.M., Radiation hybrid mapping: a somatic-cell genetic method for constructing high-resolution maps of mammalian chromosomes. Science, 250, 245-250 (1990).
7. DAFFADA, A.A.I., JOHNSTON, S.R.D., SMITH, I.E., DETRE, S., KING, N. and DOWSETT, M., Exon-5-deletion-variant-estrogen-receptor messenger RNA expression in relation to tamoxifen resistance and progesterone-receptor/ pS2 status in human breast cancer. Cancer Res., 55, 288-293 (1995).
8. DICKSON, R.B. and LIPPMAN, M.E., Growth factors in breast cancer. Endocr. Rev., 16, 559-589 (1995).
9. DORSSERS, L.C.J., VAN AGTHOVEN, T., DEKKER, A., VAN AGTHOVEN, T.L.A. and KOK, E.M., Induction of anti-estrogen resistance in human breastcancer cells by random insertional mutagenesis using defective retroviruses: identification of bear-1, a common integration site. Mol Endocrinol., 7, 870-878 (1993).
10. DORSSERS, L.C.J., VAN AGTHOVEN, T. and SIEUWERTS, A.M., Genetic mechanisms involved in progression to hormone independence of human breast cancer. In: P.M.J.J. Berns, J.C. Romijn and F.H. Schroeder (eds.), Mechanisms of progression to hormone-independent growth of breast and prostatic cancer, pp. 169-182, Parthenon. Carnforth. UK (1991).
11. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339, 1-15, 71-85 (1992).
12. EUDEMS, E.W.H.M., BORST, P., JONGSMA, A.P.M., DE JONG, S., DE VRIES, E.G.E., VAN GROENIGEN, M., VERSANTVOORT, C.H.M., NIEUWINT, A.W.M. and BAAS, F., Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype. Proc. not. Acad. Sci. (Wash.), 89, 3498-3502 (1992).
13. GOFF, S.P., Gene isolation by retroviral tagging. Methods. Enzymol., 152, 469-481 (1987).
14. Goss, S.J. and HARRIS, H., New method for mapping genes in human chromosomes. Nature (Lond.), 255, 680-684 (1975).
15. HABETS, G.G.M., SCHOLTES, E.H.M., ZUYDGEEST, D., VAN DER KAMMEN, R.A., STAM, J.C., BERNS, A. and COLLARD, J.G., Identification of an invasion-inducing gene. Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins. Cell, 77, 537-549 (1994).
16. HINEGARDNER, R.T., An improved fluorometric assay for DNA. Anal. Biochem., 39, 197-201 (1971).
17. HORWITZ, K.B., Mechanisms of hormone resistance in breast cancer. Breast Cancer Res. Treat., 26, 119-130 (1993).
18. JOHNSTON, S.R.D., HAYNES, B.P., SMITH, I.E., JARMAN, M., SACKS, N.P.M., EBBS, S.R. and DOWSETT, M., Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet, 342, 1521-1522 (1993).
19. JONKERS, J. and BERNS, A., Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim. biophys. Acta Rev. Cancer, 1287, 29-57 (1996).
20. JORDAN, V.C. and MURPHY, C.S., Endocrine pharmacology of anti-estrogens as anti-tumor agents. Endocr. Rev., 11, 578-610 (1990).
21. KARNIK, P.S., KULKARNI, S., LIU, X.P., BUDD, G.T. and BUKOWSKI, R.M., Estrogen-receptor mutations in tamoxifen-resistant breast cancer. Cancer Res., 54, 349-353 (1994).
22. KATZENELLENBOGEN, J.A., O'MALLEY, B.W. and KATZENELLENBOGEN, B.S., Tripartite-steroid-hormone-receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol., 10, 119-131 (1996).
23. KOI, M., JOHNSON, L.A., KALIKIN, L.M., LITTLE, P.F.R., NAKAMURA, Y. and FEINBERG, A.P., Tumor-cell-growth arrest caused by sub-chromosomal transferable DNA fragments from chromosome 11. Science, 260, 361-364 (1993).
24. KUNG, H.J., BOERKOEL, C. and CARTER, T.H., Retroviral mutagenesis of cellular oncogenes: a review with insights into the mechanisms of insertional activation. Curr. Top. Microbiol. Immunol., 171, 1-25 (1991).
25. LEACH. R.J. and O'CONNELL, P., Mapping of mammalian genomes with radiation (Goss and Harris) hybrids. Advanc. Genetics, 33, 63-99 (1995).
26. LIANG, P., BAUER, D., AVERBOUKH, L., WARTHOE, P., ROHRWILD, M., MULLER, H., STRAUSS, M. and FARDEE, A.B., Analysis of altered gene expression by differential display. Methods Enzymol., 254, 304-321 (1995).
27. LISITSYN, N. and WIGLER, M., Cloning the differences between two complex genomes. Science, 259, 946-951 (1993).
28. MANGELSDORF, D.J., THUMMEL, C., BEATO, M., HERRLICH, P., SCHÜTZ, G., UMESONO, K., BLUMBERG, B., KASTNER, P., MARK, M., CHAMBON, P. and EVANS, R.M., The nuclear receptor superfamily: the second decade. Cell, 83, 835-839 (1995).
29. MCGUIRE, W.L., CHAMNESS, G.C. and FUQUA, S.A.W., Estrogen-receptor variants in clinical breast cancer. Mol. Endocrino., 5, 1571-1577 (1991).
30. MLRPHY, L.C., HILSENBECK, S.G., DOTZLANV, H. and FUQUA, S.A.W., Relationship of clone-4 estrogen-receptor-variant messenger-RNA expression to some known prognostic variables in human breast cancer. Clin. Cancer Res., 1, 155-159 (1995).
31. 1 to complete the cell cycle. P roc. nat. Acad. Sci. (Wash.), 91, 8022-8026 (1994).
32. NICHOLSON, S., HALCROW, P., FARNDON, J.R., SAINSBURY, J.R.C., CHAMBERS, P. and HARRIS, A.L., Expression of epidermal-growth-factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet, I, 182-185 (1989).
33. OSBORNE, C.K., CORONADO, E., ALLRED, D.C., WIEBE, V. and DEGREGORIO, M., Acquired tamoxifen resistance: correlation with reduced breast-tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J. nat. Cancer Inst., 83, 1477-1482 (1991).
34. PAIK, S., HARTMANN, O.P., DICKSON, R.B. and LIPPMAN, M.E., Antiestrogen resistance in ER-positive breast-cancer cells. Breast Cancer Res. Treat., 31, 301-307 (1994).
35. PRITCHARD, K.I. and SUTHERLAND, D.J.A., The use of endocrine therapy. Hematol. Oncol Clin. North Amer., 3, 765-805 (1989).
36. ROODI, N., BAILEY, L.R., KAO, W.-Y, VERRIER, C.S., YEE, C.J., DUPONT, W.D. and PARL, F.F., Estrogen-receptor-gene analysis in estrogen-receptor-positive and -receptor-negative primary breast cancer. J. nat. Cancer Inst., 87, 446-451 (1995).
37. SANTEN, R.J., MANNI, A., HARVEY, H. and REDMOND, C., Endocrine treatment of breast cancer in women. Endocr. Rev., 11, 221-265 (1990).
38. TE RIELE, H., ROBANUS-MAANDAG, E., CLARKE, A., HOOPER, M. and BERNS, A., Consecutive inactivation of both alleles of the pim-1 proto-oncogene by homologous recombination in embryonic stem cells. Nature (Lond), 348, 649-651 (1990).
39. TLSTY, T.D., WHITE, A. and SANCHEZ, J., Suppression of eene amplification in human cell hybrids. Science. 255, 1425-1427 (1992).
40. TOI, M., HARRIS, A.L. and BICKNELL, R., cDNA iransfection followed by the isolation of a MCF-7 breast cell line resistant to tamoxifen in vitro and in vivo. Brit. J. Cancer, 68, 1088-1096 (1993).
41. ULLRICH, A. and SCHLESSINGER, J., Signal transduction by receptors with tyrosine-kinase activity. Cell, 61, 203-212 (1990).
42. VAN AGTHOVEN, T., VAN AGTHOVEN, T.L.A., DEKKER, A., FOHKHNS, J.A. and DORSSERS, L.C.J., Induction of estrogen independence of ZR-75-1 human breast-cancer cells by epigenetic alterations. Moi. Endocrinol., 8, 1474-1483 (1994).
43. VAN AGTHOVEN, T., VAN AGTHOVEN, T.L.A., PORTENGEN, H., FOEKENS, J.A. and DORSSERS. L.C.J., Ectopic expression of epidermal-growth-factor receptors induces hormone independence in ZR-75-1 human breast-cancer cells. Cancer Res., 52, 5082-5088 (1992).
44. WALTER, M.A. and GOODFELLOW, P.N., Radiation hybrids: irradiation and fusion gene transfer. Trends Genet., 9, 352-356 (1993).
45. WEISSMAN, B.E., SAXON, P.J., PASQUALE, S.R., JONES, G.R., GEISER, A.G. and STANBRIDGE, E.J., Introduction of a normal human chromosome 11 into a Wilms' tumor cell line controls its tumorigenic expression. Science, 236, 175-180 (1987).
46. WELCH, D.R., CHEN, P., MIELE, M.E., MCGARY, C.T., BOWER, J.M., STANBRIDGE, E.J. and WEISSMAN, B.E., Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorisenicity. Oncoqene. 9, 255-262 (1994).